source
- City Therapeutics plans $158 million IPO as Iambic eyes $135 million Nasdaq debutCity Therapeutics, an RNAi startup founded by former Alnylam Pharmaceuticals executives, announced plans for an initial public offering targeting roughly $158 million. The company intends to sell a…
- Curium lists Bexlutry at $63,524 per infusion, roughly 5% cheaper than Novartis' LutatheraCurium announced the list price for its radioligand Bexlutry, a generic version of Novartis' Lutathera. The price is set at $63,524 per infusion, which represents about a five percent discount com…